- category:Pipeline
Pipeline
Positive 6-month results reported in OASIS extension trial for CLS-AX
Latest data finds a 77% to 85% reduction in treatment burden over time period.
Pipeline
FDA clears HuidaGene for IND, multi-national IRD trial
Company plans to analyze HG004 as treatment for patients with inherited retinal dystrophies linked to the RPE65 mutations.
Pipeline
Prototype designed to prevent contact lens-induced dry eye
New contact lens prototype targets ocular dryness via tear flow.
Pipeline
FDA accepts Oxular’s IND for DME treatment
Pre-clinical data shows OXU-001 can provide up to 12 months of tolerability with just a single administered dose.
Pipeline
Ocuphire releases topline data from phase 2 trial for DR
Results from the ZETA-1 trial of oral APX330 demonstrate favorable safety and tolerability.
Pipeline
Short-term data reported in case series of SING IMT for AMD
Safety and efficacy outcomes show 3-month data from the first and largest single-surgeon cases series.
Pipeline
Horizon releases phase 2 trial results of dazodalibep for Sjögren’s syndrome
The second of two population studies met its primary endpoint.
Pipeline
First patient dosed in phase 1 study for CED treatment
Trial is assessing Trefoil Therapeutics’ lead investigational candidate: TTHX114.
Pipeline
Positive data for Glaukos’s iDose TR exchange trial
Results highlight favorable safety and tolerability for the IOP-lowering implant.
Pipeline
Eyenovia releases positive data on Optejet delivery system for glaucoma treatment
New study compares effectiveness of glaucoma medication administered via the company’s delivery system versus standard or conventional drops.
Pipeline
Glaukos reports positive clinical data for phase 2a first-in-human DED trial
Topline data shows promising results for investigational drug GLK-301, a patent cream-based formulation.
Pipeline
Positive topline phase 2 data reported for PCED treatment
A total of 67% of subjects receiving NEXAGON achieved complete epithelial recovery.
Pipeline
Opus Genetics acquires rights to Iveric Bio gene therapy candidates
Deal builds on the company’s existing portfolio of AAV-based gene therapies for inherited retinal diseases.
Pipeline
Orasis Pharmaceuticals submits NDA for CSF-1 for the treatment of presbyopia
Could a new presbyopia drug be coming?
Pipeline
FDA accepts Kala Pharmaceuticals’ IND application for PCED treatment
The company plans on initiating enrollment for a phase 2b trial this quarter.
Pipeline
Aldeyra submits NDA for primary vitreoretinal lymphoma treatment
ADX-2191 has already received Orphan Drug and Fast Track designation from the FDA.
Pipeline
Iveric Bio completes NDA submission of Zimura
Zimura is the first and currently only therapy to receive Breakthrough Therapy Designation for GA secondary to AMD.
Pipeline
FDA accepts Eyenovia’s NDA for MydCombi for in-office mydriasis
A PDUFA action target date is set for May 8, 2023.
Pipeline
FDA approves Théa Pharma’s Iyuzeh for glaucoma
The new approval targets patients with elevated IOP in OAG and ocular hypertension.
Pipeline